BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 34791636)

  • 1. Inhibition of the bromodomain and extra-terminal family of epigenetic regulators as a promising therapeutic approach for gastric cancer.
    Kang SK; Bae HJ; Kwon WS; Kim TS; Kim KH; Park S; Yu SY; Hwang J; Park J; Chung HC; Rha SY
    Cell Oncol (Dordr); 2021 Dec; 44(6):1387-1403. PubMed ID: 34791636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new BET inhibitor, 171, inhibits tumor growth through cell proliferation inhibition more than apoptosis induction.
    Damaneh MS; Hu JP; Huan XJ; Song SS; Tian CQ; Chen DQ; Meng T; Chen YL; Shen JK; Xiong B; Miao ZH; Wang YQ
    Invest New Drugs; 2020 Jun; 38(3):700-713. PubMed ID: 31267379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcriptome analysis of iBET-151, a BET inhibitor alone and in combination with paclitaxel in gastric cancer cells.
    Kang SK; Bae HJ; Kwon WS; Che J; Kim TS; Chung HC; Rha SY
    Genomics Inform; 2020 Dec; 18(4):e37. PubMed ID: 33412753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of 1-(5-(1H-benzo[d]imidazole-2-yl)-2,4-dimethyl-1H-pyrrol-3-yl)ethan-1-one derivatives as novel and potent bromodomain and extra-terminal (BET) inhibitors with anticancer efficacy.
    Kong B; Zhu Z; Li H; Hong Q; Wang C; Ma Y; Zheng W; Jiang F; Zhang Z; Ran T; Bian Y; Yang N; Lu T; Zhu J; Tang W; Chen Y
    Eur J Med Chem; 2022 Jan; 227():113953. PubMed ID: 34731760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PI3K-targeting strategy using alpelisib to enhance the antitumor effect of paclitaxel in human gastric cancer.
    Kim KJ; Kim JW; Sung JH; Suh KJ; Lee JY; Kim SH; Lee JO; Kim JW; Kim YJ; Kim JH; Bang SM; Lee JS; Kim HK; Lee KW
    Sci Rep; 2020 Jul; 10(1):12308. PubMed ID: 32704014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted Therapy of
    Chen J; Nelson C; Wong M; Tee AE; Liu PY; La T; Fletcher JI; Kamili A; Mayoh C; Bartenhagen C; Trahair TN; Xu N; Jayatilleke N; Wong M; Peng H; Atmadibrata B; Cheung BB; Lan Q; Bryan TM; Mestdagh P; Vandesompele J; Combaret V; Boeva V; Wang JY; Janoueix-Lerosey I; Cowley MJ; MacKenzie KL; Dolnikov A; Li J; Polly P; Marshall GM; Reddel RR; Norris MD; Haber M; Fischer M; Zhang XD; Pickett HA; Liu T
    Clin Cancer Res; 2021 Mar; 27(5):1438-1451. PubMed ID: 33310889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of Bromodomain and Extraterminal Domain is Associated with Progression, Metastasis and Unfavorable Outcomes: Highlighting Prognostic and Therapeutic Value of the BET Protein Family in Gastric Cancer.
    Fard SS; Kouchaki S; Salimian Z; Sotoudeh M; Mousavi SA; Alimoghaddam K; Ghaffari SH
    Anticancer Agents Med Chem; 2023; 23(7):794-806. PubMed ID: 36284375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibiting casein kinase 2 overcomes paclitaxel resistance in gastric cancer.
    Jung M; Park KH; Kim HM; Kim TS; Zhang X; Park SM; Beom SH; Kim HS; Cheong JH; Chung HC; Soong J; Lin SC; Rha SY
    Gastric Cancer; 2019 Nov; 22(6):1153-1163. PubMed ID: 31098863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic apoptotic effects of silibinin in enhancing paclitaxel toxicity in human gastric cancer cell lines.
    Zhang Y; Ge Y; Ping X; Yu M; Lou D; Shi W
    Mol Med Rep; 2018 Aug; 18(2):1835-1841. PubMed ID: 29901126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological and molecular effects of bromodomain and extra-terminal (BET) inhibitors JQ1, IBET-151, and IBET-762 in OSCC cells.
    Baldan F; Allegri L; Lazarevic M; Catia M; Milosevic M; Damante G; Milasin J
    J Oral Pathol Med; 2019 Mar; 48(3):214-221. PubMed ID: 30618144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic Upregulation of Metallothionein 2A by Diallyl Trisulfide Enhances Chemosensitivity of Human Gastric Cancer Cells to Docetaxel Through Attenuating NF-κB Activation.
    Pan Y; Lin S; Xing R; Zhu M; Lin B; Cui J; Li W; Gao J; Shen L; Zhao Y; Guo M; Wang JM; Huang J; Lu Y
    Antioxid Redox Signal; 2016 May; 24(15):839-54. PubMed ID: 26801633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BET inhibitors combined with chemotherapy synergistically inhibit the growth of NSCLC cells.
    Zhou X; Sun T; Meng Y; Luo J; Chen J; Xia B; Zhang Z; Cheng Z; Wang X
    Oncol Rep; 2021 May; 45(5):. PubMed ID: 33760217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma.
    Kling MJ; Kesherwani V; Mishra NK; Alexander G; McIntyre EM; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
    J Exp Clin Cancer Res; 2022 Nov; 41(1):321. PubMed ID: 36357906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TEAD4 modulated LncRNA MNX1-AS1 contributes to gastric cancer progression partly through suppressing BTG2 and activating BCL2.
    Shuai Y; Ma Z; Liu W; Yu T; Yan C; Jiang H; Tian S; Xu T; Shu Y
    Mol Cancer; 2020 Jan; 19(1):6. PubMed ID: 31924214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer.
    Jing X; Shao S; Zhang Y; Luo A; Zhao L; Zhang L; Gu S; Zhao X
    Exp Cell Res; 2020 Jul; 392(2):112034. PubMed ID: 32339606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-targeting BET bromodomain BRD4 and RAC1 suppresses growth, stemness and tumorigenesis by disrupting the c-MYC-G9a-FTH1axis and downregulating HDAC1 in molecular subtypes of breast cancer.
    Ali A; Shafarin J; Unnikannan H; Al-Jabi N; Jabal RA; Bajbouj K; Muhammad JS; Hamad M
    Int J Biol Sci; 2021; 17(15):4474-4492. PubMed ID: 34803511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitochondrial ROS accumulation inhibiting JAK2/STAT3 pathway is a critical modulator of CYT997-induced autophagy and apoptosis in gastric cancer.
    Cao Y; Wang J; Tian H; Fu GH
    J Exp Clin Cancer Res; 2020 Jun; 39(1):119. PubMed ID: 32576206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circular RNA circ-DONSON facilitates gastric cancer growth and invasion via NURF complex dependent activation of transcription factor SOX4.
    Ding L; Zhao Y; Dang S; Wang Y; Li X; Yu X; Li Z; Wei J; Liu M; Li G
    Mol Cancer; 2019 Mar; 18(1):45. PubMed ID: 30922402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
    Faivre EJ; McDaniel KF; Albert DH; Mantena SR; Plotnik JP; Wilcox D; Zhang L; Bui MH; Sheppard GS; Wang L; Sehgal V; Lin X; Huang X; Lu X; Uziel T; Hessler P; Lam LT; Bellin RJ; Mehta G; Fidanze S; Pratt JK; Liu D; Hasvold LA; Sun C; Panchal SC; Nicolette JJ; Fossey SL; Park CH; Longenecker K; Bigelow L; Torrent M; Rosenberg SH; Kati WM; Shen Y
    Nature; 2020 Feb; 578(7794):306-310. PubMed ID: 31969702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins.
    Lockwood WW; Zejnullahu K; Bradner JE; Varmus H
    Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19408-13. PubMed ID: 23129625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.